Anti-CRISPR-mediated Acylation and Bioreversible Esterification for Precision Genome Editing
Anti-CRISPR-mediated Acylation and Bioreversible Esterification for Precision Genome Editing
批准号:
10536799
负责人:
Axel O Vera
金额:
$4.68万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2025-06-30
关键词:
Acetyl Coenzyme AAcylationAddressBacteriaBacteriophagesBasic ScienceBindingCell Culture TechniquesCellsChargeChromosomal translocationClustered Regularly Interspaced Short Palindromic RepeatsCoenzyme AComputer AnalysisConfocal MicroscopyCytosolDNADetectionDevelopmentElectroporationEnzymesEsterificationExposure toFellowshipFluorescence MicroscopyGenomeGoalsGuide RNAHumanHydrolysisImmunityInstitutesLeadLearningLiquid ChromatographyLysineMammalian CellMasksMass Spectrum AnalysisMediatingMedicineMethodsOutcomePhosphinesProteinsResearchRibonucleoproteinsSiteSpecificitySystemTestingTherapeuticTimeUnited States National Institutes of HealthViralbasediazo compoundendonucleaseesteraseexposed human populationgenome editinggenotoxicityin vivoinhibitornext generation sequencingnovelnovel strategiespreventprogramsresponsesmall moleculespatiotemporaltandem mass spectrometryvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems use
RNA-guided proteins (e.g., Cas9, Cas12a) to cleave DNA. Cas9 and Cas12a share many similarities and have
been repurposed for genome editing in human cells because of their programmability, simplicity, and
efficiency, with applications in basic research and medicine. Cas12a is generally more efficient and specific
than Cas9. However, since the concentration of Cas protein is much higher than that of the DNA target in
genome editing, prolonged Cas12a activity also leads to off-target DNA cleavage, chromosomal translocations,
and genotoxicity.
Equipping Cas12a with an “on-off” switch can overcome these challenges by shortening Cas12a’s window of
exposure and increasing its specificity—the on-target to off-target ratio of DNA cleavage. We developed a
novel strategy that repurposes a CRISPR-Cas inhibitor protein (i.e., an anti-CRISPR) to selectively acylate or
“cage” Cas12a with a small-molecule-removable group. We propose to deliver small molecules and anti-
CRISPR proteins into human cells via fast, bioreversible, and in vivo-compatible means to activate and
inactivate Cas12a, respectively, and increase its specificity. With the help of experts at the outstanding MIT
and Broad Institute facilities, I will learn how to use liquid chromatography–tandem mass spectrometry
(LC–MS/MS) to assess the selectivity of our novel Cas12a acylation strategy, and mammalian cell culture, high
throughput confocal microscopy, next-generation sequencing, and computational analysis to assess
anti-CRISPR delivery and Cas12a genome-editing specificity. Overall, this research will introduce the first
approach for the site-selective and reversible acylation of Cas12a lysine residues and a new bioreversible
esterification strategy for the traceless delivery of anti-CRISPR proteins that together will increase genome-
editing specificity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anti-CRISPR-mediated Acylation and Bioreversible Esterification for Precision Genome Editing
-
批准号:10657417
-
项目类别:
-
资助金额:$2.27万
-
财政年份:2022
-
负责人:Axel O Vera
-
依托单位:
海外基金